Chromatography systems and columns constitute the core equipment within the separation and purification stages of biopharmaceutical manufacturing. Primarily utilized for the precise separation, purification, and concentration of biological macromolecules—such as proteins, antibodies, nucleic acids, and plasmids—these systems are widely deployed in the production processes of vaccines, antibody therapeutics, mRNA-based drugs, and similar products. A chromatography system comprises a delivery pump, injector, chromatography column, detector, fraction collector, and control unit; it facilitates automated gradient elution, real-time online monitoring, and component collection, thereby ensuring the stability and reproducibility of the separation process. As the central component of the separation process, the chromatography column consists of a column tube, frits, connectors, and other elements. Columns are categorized based on their separation mechanisms—including ion exchange, gel filtration, and affinity chromatography—to accommodate the separation requirements of target products with diverse molecular weights and physicochemical properties. The efficiency and resolution of the column directly determine the purity and yield of the final product. Furthermore, columns are available in various specifications—ranging from analytical to preparative scales—to satisfy the diverse needs of laboratory R&D, pilot-scale trials, and industrial-scale mass production; they can also be seamlessly integrated with downstream ultrafiltration systems to establish a comprehensive and complete purification process chain.

Tangential Flow Filtration (TFF) is a pivotal technology in biopharmaceuticals for sample concentration, desalting, buffer exchange, and impurity removal. Renowned for its high efficiency, gentle processing, and scalability, it is widely employed in the downstream processing of various biological products, including proteins, antibodies, mRNA, and viruses. Its core principle involves using a pump to drive the feed stream tangentially across the surface of a filtration membrane, thereby achieving separation based on molecular size differences under pressure. This tangential flow effectively scours the membrane surface, mitigating concentration polarization and membrane fouling while simultaneously preserving the biological activity of the target product and preventing structural damage caused by high shear forces. TFF systems are categorized by production scale—ranging from laboratory-grade to pilot/production-grade and industrial-grade—encompassing a diverse spectrum of membrane surface areas and processing capacities. Key control parameters—such as tangential flow rate, Transmembrane Pressure (TMP), temperature, and pH—can be precisely regulated to optimize filtration performance. By accommodating ultrafiltration membranes with varying molecular weight cut-offs, TFF offers the flexibility to effectively concentrate and enrich target products while removing small-molecule impurities (such as salts and unreacted substrates). As a critical link connecting chromatographic purification with subsequent formulation stages, TFF significantly enhances both production efficiency and product quality stability.

Single-use systems and kits represent a standardized solution developed within the biopharmaceutical sector to mitigate cross-contamination risks, streamline validation processes, and enhance manufacturing flexibility. These systems are widely deployed across the entire biopharmaceutical production lifecycle, proving particularly well-suited for the manufacture of products with exceptionally stringent sterility requirements—such as vaccines, cell therapies, and mRNA-based therapeutics. Comprising components such as single-use tubing, fittings, connectors, valves, storage bags, filters, bioreactor bags, and filling lines, these systems allow for the customized design of fluid pathways and specifications to meet specific process requirements. Furthermore, all components undergo rigorous irradiation sterilization and are supplied in a sterile, ready-to-use state. The core advantage of these systems lies in eliminating the need for Cleaning-in-Place (CIP) and Sterilization-in-Place (SIP) validation; this effectively reduces the time and cost expenditures associated with equipment cleaning and sterilization, while simultaneously eradicating the risk of cross-contamination between different product batches. Moreover, the materials used for all components comply with strict biocompatibility standards and have undergone comprehensive validation for leachables and extractables, thereby ensuring that the quality and biological activity of the target product remain unaffected. Adaptable to a diverse range of process scenarios—including fluid transfer, sampling, media preparation, filtration, and filling—these systems strike an optimal balance between operational flexibility and regulatory compliance, thereby facilitating the efficient and standardized execution of biopharmaceutical manufacturing workflows.

This segment encompasses the core upstream and midstream production processes within biopharmaceuticals—particularly for mRNA vaccines and gene therapy products. It constitutes a critical pathway extending from raw material preparation to the formation of formulation intermediates, wherein each step is tightly integrated and coordinated to directly determine the product's quality and yield. Microbial fermentation serves as the foundational basis for preparing raw materials such as plasmid templates; utilizing seed tanks and fermenters, this process facilitates the resuscitation, amplification, and large-scale cultivation of microbial strains. Parameters such as culture medium composition, temperature, pH, and dissolved oxygen concentration are strictly controlled to ensure efficient microbial growth and the high-level expression of target products (e.g., plasmids). Microbial lysis is subsequently performed using high-pressure homogenization or alkaline lysis methods; lysis conditions are precisely controlled to release intracellular target products while simultaneously preventing product degradation, thereby laying the groundwork for subsequent purification. In vitro transcription (IVT) constitutes the core step in mRNA preparation; utilizing linearized plasmids as templates and catalyzed by polymerases, this process synthesizes mRNA while simultaneously performing capping and tailing modifications. Through the precise control of reaction parameters and raw material quality, the high purity, activity, and stability of the resulting mRNA are ensured. Finally, lipid nanoparticle (LNP) encapsulation represents a critical stage in the mRNA delivery system; by encapsulating the mRNA within nanoparticles composed of ionizable lipids, cholesterol, and phospholipids, the process effectively protects the mRNA from degradation by RNases and facilitates its entry into—and subsequent release within—target cells. The encapsulation process requires strict control over particle size uniformity and encapsulation efficiency to ensure the safety and efficacy of the final formulation intermediate. Collectively, this entire workflow enables linear scalability from laboratory-scale R&D to industrial-grade manufacturing, thereby meeting the demands of large-scale production.

Compliance with ASME BPE and 21 CFR Part 11 constitutes the core regulatory imperative that biopharmaceutical equipment and production processes must satisfy. By ensuring the standardization of production processes, the reliability of data, and the safety of products, this compliance serves as a prerequisite for enterprises seeking to pass audits by domestic and international pharmaceutical regulatory bodies and to achieve large-scale production. ASME BPE (the American Society of Mechanical Engineers’ Bioprocessing Equipment Standard) stands as the world's leading standard for the design, manufacture, and inspection of biopharmaceutical equipment. It encompasses comprehensive requirements spanning material selection, structural design, surface finishes, welding processes, and traceability. For instance, the standard mandates the use of high-purity 316L stainless steel for equipment materials and requires surface roughness to meet rigorous criteria; this ensures that equipment is free of dead legs, easy to clean, and devoid of contaminant residues—thereby mitigating contamination risks at the source—while simultaneously supporting equipment verifiability and scalability to align with the stringent hygienic requirements of biopharmaceutical manufacturing [superscript:9][superscript:10]. 21 CFR Part 11 is a regulation issued by the U.S. FDA governing the management of electronic records and electronic signatures. It mandates that electronic records generated during biopharmaceutical production—such as process parameters, analytical data, and equipment operation logs—hold the same legal validity as handwritten signatures. Compliance requires the implementation of features such as system validation, audit trails, tamper-proofing, access controls, and long-term readability to ensure the authenticity, integrity, and traceability of data, thereby preventing data falsification or loss. Furthermore, the regulation standardizes the use of electronic signatures, enabling the traceability of operational actions. Acting in concert, these two standards establish a robust compliance assurance framework for biopharmaceutical production, empowering enterprises to meet global pharmaceutical regulatory requirements and enhancing both their product competitiveness and market recognition.